51
|
Lu S, Qin S, Zhou Z, Chen J, Gu K, Sun P, Pan Y, Yu G, Ma K, Shi J, Sun Y, Yang L, Chen P, Liu A, He J. Bevacizumab biosimilar candidate TAB008 compared to Avastin ® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. J Cancer Res Clin Oncol 2023; 149:5907-5914. [PMID: 36595042 DOI: 10.1007/s00432-022-04563-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 12/26/2022] [Indexed: 01/04/2023]
Abstract
BACKGROUND Bevacizumab (Avastin®) is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). Used alone or in combination with chemotherapy and/or immunotherapy, Avastin® has shown promising efficacy in many cancers. This study compared the efficacy and safety of TAB008 with Avastin® sourced from the EU (bevacizumab-EU), in patients with non-squamous non-small cell lung cancer (nsNSCLC). METHOD In this randomized, double-blind, multicenter, phase III similarity study, treatment naïve for metastatic lung cancer., EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (nsNSCLC) patients were enrolled and randomized (1:1) into TAB008 or Avastin® groups. Patients received TAB008 or Avastin® 15 mg/kg intravenously plus paclitaxel/carboplatin for 4-6 cycles followed by TAB008 or Avastin® 7.5 mg/kg until disease progression, unacceptable toxicity or death. The primary endpoint compared the objective response rate (ORR) within 6 cycles as read by an independent radiological review committee (IRRC). Secondary endpoints compared disease control rate (DCR) Within 6 cycles, duration of response (DoR), progression-free survival (PFS), a year overall survival rate (OSR), overall survival (OS), safety, immunogenicity, and steady-state pharmacokinetics. RESULTS A total of 549 nsNSCLC patients were enrolled (277 in TAB008 group and 272 in Avastin® group). In the full analysis set, ORRs were 55.957% for TAB008 and 55.720% for Avastin®, and the ORR ratio was 1 (90% CI 0.89-1.14), well within the predefined equivalence margin of 0.75-1.33. No significant differences were found in DCR within 6 cycles (95.703% vs 95.367%, p = 0.8536), DoR (8.17 vs 7.3 months, p = 0.3526), PFS (9.10 vs. 7.97 months, p = 0.9457), 1 year overall survival rate (66.2% vs 68%, p = 0.6793), or OS (20.4 vs 17.6 months, p = 0.6549). Serious adverse events (SAEs) occurred in 37.55% (104/277) of patients in the TAB008 group and 34.32% (93/271) in the Avastin® group. Anti-drug antibodies were reported in 3 of 277 (1.08%) TAB008 patients, and 5 of 271 (1.85%) Avastin® patients, neutralizing antibody (Nab) was positive in 1 patient on Avastin®, which became negative upon follow-up. The steady-state trough concentrations (Cssmin) were 106.13 μg/mL in TAB008 group and 96.03 μg/mL in Avastin® groups, with the treatment group ratio of LS geometric means fully contained within the bioequivalence limits of 80.00-125.00% (90% CI was 101.74-120.05%). CONCLUSIONS TAB008 is similar to Avastin® in terms of efficacy, safety, and pharmacokinetic parameters, with comparable immunogenicity. TRIAL REGISTRATION ClinicalTrials.gov number; NCT05427305.
Collapse
|
52
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Akiba K, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blank JE, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Cicco A, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski LF, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Liu Y, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Mackowiak P, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Waldi R, Walsh J, Wan G, Wang C, Wang G, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wu J, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. First Observation of a Doubly Charged Tetraquark and Its Neutral Partner. PHYSICAL REVIEW LETTERS 2023; 131:041902. [PMID: 37566831 DOI: 10.1103/physrevlett.131.041902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 01/23/2023] [Indexed: 08/13/2023]
Abstract
A combined amplitude analysis is performed for the decays B^{0}→D[over ¯]^{0}D_{s}^{+}π^{-} and B^{+}→D^{-}D_{s}^{+}π^{+}, which are related by isospin symmetry. The analysis is based on data collected by the LHCb detector in proton-proton collisions at center-of-mass energies of 7, 8, and 13 TeV. The full data sample corresponds to an integrated luminosity of 9 fb^{-1}. Two new resonant states with masses of 2.908±0.011±0.020 GeV and widths of 0.136±0.023±0.013 GeV are observed, which decay to D_{s}^{+}π^{+} and D_{s}^{+}π^{-} respectively. The former state indicates the first observation of a doubly charged open-charm tetraquark state with minimal quark content [cs[over ¯]ud[over ¯]], and the latter state is a neutral tetraquark composed of [cs[over ¯]u[over ¯]d] quarks. Both states are found to have spin-parity of 0^{+}, and their resonant parameters are consistent with each other, which suggests that they belong to an isospin triplet.
Collapse
|
53
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Akiba K, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blank JE, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski LF, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Mackowiak P, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Su YS, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Waldi R, Walsh J, Wan G, Wang C, Wang G, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wu J, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Search for Rare Decays of D^{0} Mesons into Two Muons. PHYSICAL REVIEW LETTERS 2023; 131:041804. [PMID: 37566853 DOI: 10.1103/physrevlett.131.041804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 05/18/2023] [Indexed: 08/13/2023]
Abstract
A search for the very rare D^{0}→μ^{+}μ^{-} decay is performed using data collected by the LHCb experiment in proton-proton collisions at sqrt[s]=7, 8, and 13 TeV, corresponding to an integrated luminosity of 9 fb^{-1}. The search is optimized for D^{0} mesons from D^{*+}→D^{0}π^{+} decays but is also sensitive to D^{0} mesons from other sources. No evidence for an excess of events over the expected background is observed. An upper limit on the branching fraction of this decay is set at B(D^{0}→μ^{+}μ^{-})<3.1×10^{-9} at a 90% C.L. This represents the world's most stringent limit, constraining models of physics beyond the standard model.
Collapse
|
54
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Akiba K, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Ao D, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Camargo Magalhaes P, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Coombs G, Corredoira I, Corti G, Costa Sobral CM, Couturier B, Craik DC, Crkovská J, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dall'Occo E, Dalseno J, D'Ambrosio C, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Cicco A, Di Nezza P, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Dudek MW, Dufour L, Duk V, Durante P, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Falcao LN, Fan Y, Fang B, Farry S, Fazzini D, Feo M, Fernandez Prieto A, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Gabriel E, Galati G, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Heinicke K, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang X, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kuindersma HS, Kunde GJ, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li H, Li P, Li S, Li Y, Li Z, Liang X, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu XR, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marinangeli M, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Olivares ME, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Reboud M, Redi F, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shields EB, Shimizu Y, Shmanin E, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Slazyk I, Smallwood JC, Smeaton JG, Smith E, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spiridenkov E, Spradlin P, Stagni F, Stahl M, Stahl S, Stanislaus S, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tong X, Torres Machado D, Tou DY, Trifonova E, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Ursov E, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Waldi R, Walsh J, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Wilson FF, Wislicki W, Witek M, Witola L, Wormser G, Wotton SA, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang Y, Yang Z, Yang Z, Yao Y, Yeomans LE, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Nuclear Modification Factor of Neutral Pions in the Forward and Backward Regions in p-Pb Collisions. PHYSICAL REVIEW LETTERS 2023; 131:042302. [PMID: 37566846 DOI: 10.1103/physrevlett.131.042302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 06/10/2022] [Indexed: 08/13/2023]
Abstract
The nuclear modification factor of neutral pions is measured in proton-lead collisions collected at a center-of-mass energy per nucleon of 8.16 TeV with the LHCb detector. The π^{0} production cross section is measured differentially in transverse momentum (p_{T}) for 1.5
Collapse
|
55
|
Jiang RA, Xu T, Li W, Jin LF, Zhou YM, Bai XX, He J. [Clinical analysis of 31 cases of fetal umbilical artery thrombosis]. ZHONGHUA FU CHAN KE ZA ZHI 2023; 58:495-500. [PMID: 37474322 DOI: 10.3760/cma.j.cn112141-20230106-00008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 07/22/2023]
Abstract
Objective: To analyze the ultrasonic manifestations, clinical features, high risk factors and key points of pregnancy management in prenatal diagnosis of umbilical artery thrombosis (UAT). Methods: The data of 31 pregnant women of UAT diagnosed by prenatal ultrasonography and confirmed after birth from July 2017 to July 2022 at the Women's Hospital, Zhejiang University School of Medicine were retrospectively analyzed, including the maternal characteristics, pregnancy outcomes and fetal complications. In addition, the baseline data and pregnancy outcomes were compared in 21 patients who continued pregnancy after diagnosis of UAT. Of the 21 UAT cases that continued pregnancy, 10 cases were treated with low molecular weight heparin (LMWH; LMWH treatment group), while the other 11 patients had expectant treatment(expectant treatment group). Results: The age of the 31 pregnant women was (30.2±4.7) years, of which 5 cases (16%,5/31) were advanced age pregnant women. The gestational age at diagnosis was (32.9±4.0) weeks, and the gestational age at termination of pregnancy was (35.6±2.9) weeks. In 31 fetuses with UAT, 15 cases (48%) had fetal distress, 11 cases (35%) had fetal growth restriction, and 3 cases (10%) had intrauterine stillbirth. There were 28 cases of live births, including 26 cases by cesarean section and 2 cases by vaginal delivery. There were also 3 stillbirths, all delivered vaginally. Four neonates had mild asphyxia and two newborns had severe asphyxia. Among the 31 cases, 10 cases were terminated immediately after diagnosis, the gestational age at diagnosis was (35.9±2.9) weeks. Another 21 pregnancies continued, and their gestational age at diagnosis was (31.4±3.7) weeks. The median prolonged gestational age in LMWH treatment group was 7.9 weeks (4.6-9.4 weeks), and all were live births. The median prolonged gestational age in the expectant treatment group was 0.6 weeks (0.0-1.0 weeks), and 2 cases were stillbirths. There was a statistically significant difference in prolonged gestational age (P=0.002). Conclusions: Ultrasound is the preferred method for prenatal detection of UAT. Clinicians need to be vigilant for UAT when a newly identified single umbilical artery is detected by ultrasound in the second or third trimesters. The decision to continue or terminate the pregnancy depends on the gestational age and the condition of fetus. Attention should be paid to fetal movements as the pregnancy continues. The treatment of LMWH as soon as possible after diagnosis of UAT may improve the pregnancy outcome.
Collapse
|
56
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Ajaltouni Z, Akar S, Akiba K, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blank JE, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski LF, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Mackowiak P, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pilloni A, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Su YS, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Waldi R, Walsh J, Wan G, Wang C, Wang G, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wu J, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Observation of a J/ψΛ Resonance Consistent with a Strange Pentaquark Candidate in B^{-}→J/ψΛp[over ¯] Decays. PHYSICAL REVIEW LETTERS 2023; 131:031901. [PMID: 37540878 DOI: 10.1103/physrevlett.131.031901] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 01/12/2023] [Indexed: 08/06/2023]
Abstract
An amplitude analysis of B^{-}→J/ψΛp[over ¯] decays is performed using 4400 signal candidates selected on a data sample of pp collisions recorded at center-of-mass energies of 7, 8, and 13 TeV with the LHCb detector, corresponding to an integrated luminosity of 9 fb^{-1}. A narrow resonance in the J/ψΛ system, consistent with a pentaquark candidate with strangeness, is observed with high significance. The mass and the width of this new state are measured to be 4338.2±0.7±0.4 MeV and 7.0±1.2±1.3 MeV, where the first uncertainty is statistical and the second systematic. The spin is determined to be 1/2 and negative parity is preferred. Because of the small Q-value of the reaction, the most precise single measurement of the B^{-} mass to date, 5279.44±0.05±0.07 MeV, is obtained.
Collapse
|
57
|
Luo X, Cheng Y, Wu C, He J. [An interpretable machine learning-based prediction model for risk of death for patients with ischemic stroke in intensive care unit]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2023; 43:1241-1247. [PMID: 37488807 PMCID: PMC10366517 DOI: 10.12122/j.issn.1673-4254.2023.07.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/26/2023]
Abstract
OBJECTIVE To construct an inherent interpretability machine learning model as an explainable boosting machine model (EBM) for predicting one-year risk of death in patients with severe ischemic stroke. METHODS We randomly divided the data of 2369 eligible patients with severe ischemic stroke in the MIMIC-Ⅳ(2.0) database, who were admitted in ICU in 2008 to 2019, into a training dataset (80%) and a test dataset (20%), and assessed the prognosis of the patients using the EBM model. The prediction performance of the model was evaluated by calculating the area under the receiver operating characteristic (AUC) curve. The calibration curve and Brier score were used to evaluate the degree of calibration of the model, and a decision curve was generated to assess the net clinical benefit. RESULTS The EBM model constructed in this study had good discrimination power, calibration and net benefit, with an AUC of 0.857 (95% CI: 0.831-0.887) for predicting prognosis of severe ischemic stroke. Calibration curve analysis showed that the standard curve of the EBM model was the closest to the ideal curve. Decision curve analysis showed that the model had the greatest net benefit rate at the prediction probability threshold of 0.10 to 0.80. The top 5 independent predictive variables based on the EBM model were age, SOFA score, mean heart rate, mechanical ventilation, and mean respiratory rate, whose significance scores ranged from 0.179 to 0.370. CONCLUSION This EBM model has a good performance for predicting the risk of death within one year in patients with severe ischemic stroke and allows clinicians to better understand the contributing factors of the patients' outcomes through the model interpretability.
Collapse
|
58
|
Zhao YN, Fu JY, He J, Fan DS. [Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis]. ZHONGHUA NEI KE ZA ZHI 2023; 62:885-890. [PMID: 37394863 DOI: 10.3760/cma.j.cn112138-20220708-00498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
|
59
|
Zhao CG, Mu JW, He J. [A brief history of the evolution of lung cancer operation]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2023; 45:530-538. [PMID: 37355473 DOI: 10.3760/cma.j.cn112152-20220523-00364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/26/2023]
Abstract
Surgical operation is one of the significant parts of the comprehensive therapeutic methods of lung cancer. In the history of the development of lung cancer operation, scholars and predecessors at home and abroad have gradually established the current status of lung cancer operation and the framework of comprehensive treatment after continuous understanding of local anatomy of lung, continuous innovation of surgical equipment and continuous reform of surgical methods. In the continuous development and improvement of lung cancer surgical diagnosis and treatment procedures, a set of standardized diagnosis and treatment process of lung cancer screening, early diagnosis and treatment, standardized surgery process, rapid perioperative recovery, postoperative adjuvant treatment and follow-up has been formed. The achievements of lung cancer operation are achieved by scholars standing on the shoulders of giants. In the process of pioneering and innovating, we should go back and review the road that our predecessors have taken, and draw energy from it to continue to create new brilliance in lung cancer operation. In this paper, the evolution history of lung cancer surgery is summarized in order to improve the clinician's understanding of the history of lung cancer surgery.
Collapse
|
60
|
Liao W, Xiao H, He J, Huang L, Liao Y, Qin J, Yang Q, Ma F, Li S. B-Cell-Activating Factor Contributes to Elevation of the Content of Regulatory B Cells in Neonatal Sepsis. Bull Exp Biol Med 2023:10.1007/s10517-023-05814-1. [PMID: 37338768 DOI: 10.1007/s10517-023-05814-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Indexed: 06/21/2023]
Abstract
We studied the role of B cell-activating factor (BAFF) in PI3K/AKT/mTOR signaling pathway in promoting proliferation and maintaining survival of regulatory B lymphocytes (Breg) in newborns with sepsis. The peripheral blood samples were collected from preterm neonates (n=40) diagnosed with sepsis on the day of diagnosis and on days 7, 14, and 21 after diagnosis, as well as from the matched preterm neonates without sepsis (n=40; control group). The peripheral blood mononuclear cells and B cells were isolated, cultured, and stimulated with LPS and immunostimulant CpG-oligodeoxynucleotide (CpG-ODN). Proliferation and differentiation of B-cells into CD19+CD24hiCD38hi Breg cells and the role of the PI3K/AKT/mTOR signaling pathway in these processes were studied by flow cytometry, real-time quantitative reverse transcription PCR (qRT-PCR), and Western blotting. BAFF levels in the peripheral blood of neonates with sepsis were significantly increased at one week after diagnosis in parallel with increasing trend of expression of BAFF receptor. When applied with LPS and CpG-ODN, BAFF promoted differentiation of B cells into CD19+CD24hiCD38hi Breg cells. Phosphorylation of 4E-BP1 factor and 70S6K kinase located downstream in PI3K/AKT/mTOR signaling pathway was significantly up-regulated when stimulated with BAFF in combination with LPS and CpG-ODN. Thus, increased level of BAFF activates PI3K/AKT/mTOR signaling pathway and induces in vitro differentiation of peripheral blood B cells into CD19+CD24hiCD38hi Breg cells.
Collapse
|
61
|
Hao XY, Yang P, Zhang W, Liu H, Sun XH, Xiao XB, Wang JW, Li ZL, Li LH, Wang SY, He J, Li XL, Jing HM. [Clinical features and prognostic factors of elderly patients with mantle cell lymphoma]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2023; 44:495-500. [PMID: 37550206 PMCID: PMC10450559 DOI: 10.3760/cma.j.issn.0253-2727.2023.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Indexed: 08/09/2023]
Abstract
Objective: To examine the clinical characteristics and prognostic factors of elderly patients with mantle cell lymphoma (MCL) and the impact of nutrition and underlying diseases on the prognosis of elderly patients with MCL. Methods: retrospectively analyzed 255 elderly patients with MCL from 11 medical centers, including Peking University Third Hospital between January 2000 and February 2021. We analyzed clinical data, such as age, gender, Mantle Cell Lymphoma International Prognostic Index score, and treatment options, and performed univariate and multivariate prognostic analysis. We performed a comprehensive geriatric assessment on elderly MCL patients with medical records that included retraceable underlying disease and albumin levels, and we investigated the impact of basic nutrition and underlying disorders on MCL prognosis in the elderly. Results: There were 255 senior individuals among the 795 MCL patients. Elderly MCL was more common in males (78.4%), with a median age of 69 yr (ages 65-88), and the majority (88.6%) were identified at a late stage. The 3-yr overall survival (OS) rate was 42.0%, with a 21.2% progression-free survival (PFS) rate. The overall response rate (ORR) was 77.3%, with a 33.3% total remission rate. Elderly patients were more likely than younger patients to have persistent underlying illnesses, such as hypertension. Multivariate analysis revealed that variables related with poor PFS included age of ≥80 (P=0.021), Ann Arbor stage Ⅲ-Ⅳ (P=0.003), high LDH level (P=0.003), involvement of bone marrow (P=0.014). Age of ≥80 (P=0.001) and a high LDH level (P=0.003) were risk factors for OS. The complete geriatric assessment revealed that renal deficiency was associated with poorer OS (P=0.047) . Conclusions: Elderly MCL patients had greater comorbidities. Age, LDH, renal function, bone marrow involvement, and Ann Arbor stage are all independent risk factors for MCL in the elderly.
Collapse
|
62
|
Zhang L, He J, Yang F, Dang H, Li Y, Guo S, Li S, Cao C, Xu J, Li S, Zhou X. [Progress of schistosomiasis control in People's Republic of China in 2022]. ZHONGGUO XUE XI CHONG BING FANG ZHI ZA ZHI = CHINESE JOURNAL OF SCHISTOSOMIASIS CONTROL 2023; 35:217-224. [PMID: 37455091 DOI: 10.16250/j.32.1374.2023073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]
Abstract
This report presented the endemic status of schistosomiasis and analyzed the data collected from the national schistosomiasis prevention and control system and national schistosomiasis surveillance program in the People's Republic of China in 2022. Among the 12 provinces (municipality and autonomous region) endemic for schistosomiasis, Shanghai Municipality, Zhejiang Province, Fujian Province, Guangdong Province and Guangxi Zhuang Autonomous Region continued to maintain the achievements of schistosomiasis elimination, and Sichuan and Jiangsu provinces maintained the criteria of transmission interruption, while Yunnan, Hubei, Anhui, Jiangxi and Hunan provinces maintained the criteria of transmission control by the end of 2022. A total of 452 counties (cites, districts) were found to be endemic for schistosomiasis in China in 2022, with 27 434 endemic villages covering 73 424 400 people at risk of infections. Among the 452 endemic counties (cities, districts), 75.89% (343/452), 23.45% (106/452) and 0.66% (3/452) achieved the criteria of elimination, transmission interruption and transmission control of schistosomiasis, respectively. In 2022, 4 317 356 individuals received serological tests for schistosomiasis, and 62 228 were sero-positive. A total of 208 646 individuals received stool examinations for schistosomiasis, with one positive and another two cases positive for urine microscopy, and these three 3 cases were imported schistosomiasis patients from Africa. There were 28 565 cases with advanced schistosomiasis documented in China by the end of 2022. Oncomelania hupensis snail survey was performed in 18 891 endemic villages in China in 2022 and O. hupensis snails were found in 6 917 villages (36.62% of all surveyed villages), with 8 villages identified with emerging snail habitats. Snail survey was performed at an area of 655 703.01 hm2 and 183 888.60 hm2 snail habitats were found, including 110.58 hm2 emerging snail habitats and 844.35 hm2 re-emerging snail habitats. There were 477 200 bovines raised in the schistosomiasis endemic areas of China in 2022, and 113 946 bovines received serological examinations for schistosomiasis, with 204 sero-positives detected. Among the 131 715 bovines received stool examinations, no positives were identified. In 2022, there were 19 726 schistosomiasis patients receiving praziquantel chemotherapy, and expanded chemotherapy was performed in 714 465 person-time for humans and 234 737 herd-time for bovines in China. In 2022, snail control with chemical treatment was performed at an area of 119 134.07 hm2, and the actual area of chemical treatment was 65 825.27 hm2, while environmental improvements were performed at an area of 1 163.96 hm2. Data from the national schistosomiasis surveillance program of China showed that the mean prevalence of Schistosoma japonicum infections was both zero in humans and bovines in 2022, and no S. japonicum infection was detected in O. hupensis snails. These data demonstrated that the endemic status of schistosomiasis continued to decline in China in 2022, with 3 confirmed schistosomiasis patients that had a foreign nationality and all imported from Africa, and the areas of snail habitats remained high. Further improvements in the construction of the schistosomaisis surveillance and forecast system, and reinforcement of O. hupensis survey and control are required to prevent the re-emerging schistosomiasis.
Collapse
|
63
|
Zhong JM, Luo DJ, Fan J, He J, Wang X, Nie X, Zhou DW. [Clinicopathological analysis of cytological diagnosis of mesothelioma in serosal effusion]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2023; 52:612-614. [PMID: 37263927 DOI: 10.3760/cma.j.cn112151-20221018-00872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
64
|
He J, Li F, Huang WH, Wang LP, Zhang XW, Zhao Y. [Guidelines for diagnosis and treatment of glucocorticoid-induced osteoporosis]. ZHONGHUA NEI KE ZA ZHI 2023; 62:631-638. [PMID: 37263946 DOI: 10.3760/cma.j.cn112138-20221025-00787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Glucocorticoid-induced osteoporosis (GIOP) is a skeletal disease characterized by decreased bone strength and increased fracture risk associated with long-term glucocorticoid use. GIOP is the most common secondary osteoporosis that critically affects the quality of life of patients. Currently, the incidence of GIOP in China remains high, with insufficient awareness and lack of prevention and treatment norms. Therefore, the Chinese Rheumatology Association has established this standard based on domestic and international experience, with the aim of raising awareness of prevention and treatment among clinicians, guiding the standardized diagnosis and treatment of this disease, and improving the overall prognosis of patients with GIOP.
Collapse
|
65
|
He J, You E, Zhong Q, Huang F. Trends and seasonal variation of antibiotic consumption by community residents in Hefei, China, 2012-2016. Public Health 2023; 220:27-32. [PMID: 37229945 DOI: 10.1016/j.puhe.2023.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 02/13/2023] [Accepted: 04/19/2023] [Indexed: 05/27/2023]
Abstract
OBJECTIVES The aim of this study was to evaluate the trends and seasonal variations of antibiotic consumption by community residents in Hefei, China, over a 5-year period. STUDY DESIGN This was an ecological study. METHODS Data on antibiotic consumption by community residents in Hefei between 2012 and 2016 were collected from the Hefei Center for Disease Control and Prevention. Statistical analysis was carried out using Microsoft Excel 2021, SPSS 26.0 and R4.1.3. An interrupted time series (ITS) analysis was modelled to assess the impact of policies on antibiotic consumption trends. RESULTS Amoxicillin and cephalosporins accounted for 63.64% and 30.48%, respectively, of the total defined daily dose per 1000 inhabitant-days (DID) of antibiotics in 2016. The total consumption of antibiotics decreased from 6.92 DID in 2012 to 5.61 DID in 2016 (Ptrend = 0.017). Seasonal analysis showed an average of 34.24% antibiotic consumption in the winter over the 5 years. The equation constructed by the ITS analysis was Y = 5.530 + 0.323X1 - 7.574X2 - 0.323X3 + ε. CONCLUSION Between 2012 and 2016, overall antibiotic consumption by community residents in Hefei decreased significantly. The impact of antibiotic policies, implemented between 2011 and 2013, started to appear in 2014 when the consumption of antibiotics decreased. This study has important policy implications for the use of antibiotics at the community level. Further studies on the trends of antibiotic consumption are required, and strategies should be designed to promote appropriate use of antibiotics.
Collapse
|
66
|
Erchick DJ, Hazel EA, Katz J, Lee ACC, Diaz M, Wu LSF, Yoshida S, Bahl R, Grandi C, Labrique AB, Rashid M, Ahmed S, Roy AD, Haque R, Shaikh S, Baqui AH, Saha SK, Khanam R, Rahman S, Shapiro R, Zash R, Silveira MF, Buffarini R, Kolsteren P, Lachat C, Huybregts L, Roberfroid D, Zeng L, Zhu Z, He J, Qiu X, Gebreyesus SH, Tesfamariam K, Bekele D, Chan G, Baye E, Workneh F, Asante KP, Kaali EB, Adu-Afarwuah S, Dewey KG, Gyaase S, Wylie BJ, Kirkwood BR, Manu A, Thulasiraj RD, Tielsch J, Chowdhury R, Taneja S, Babu GR, Shriyan P, Ashorn P, Maleta K, Ashorn U, Mangani C, Acevedo-Gallegos S, Rodriguez-Sibaja MJ, Khatry SK, LeClerq SC, Mullany LC, Jehan F, Ilyas M, Rogerson SJ, Unger HW, Ghosh R, Musange S, Ramokolo V, Zembe-Mkabile W, Lazzerini M, Rishard M, Wang D, Fawzi WW, Minja DTR, Schmiegelow C, Masanja H, Smith E, Lusingu JPA, Msemo OA, Kabole FM, Slim SN, Keentupthai P, Mongkolchati A, Kajubi R, Kakuru A, Waiswa P, Walker D, Hamer DH, Semrau KEA, Chaponda EB, Chico RM, Banda B, Musokotwane K, Manasyan A, Pry JM, Chasekwa B, Humphrey J, Black RE. Vulnerable newborn types: analysis of subnational, population-based birth cohorts for 541 285 live births in 23 countries, 2000-2021. BJOG 2023. [PMID: 37156239 DOI: 10.1111/1471-0528.17510] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 04/04/2023] [Accepted: 04/07/2023] [Indexed: 05/10/2023]
Abstract
OBJECTIVE To examine prevalence of novel newborn types among 541 285 live births in 23 countries from 2000 to 2021. DESIGN Descriptive multi-country secondary data analysis. SETTING Subnational, population-based birth cohort studies (n = 45) in 23 low- and middle-income countries (LMICs) spanning 2000-2021. POPULATION Liveborn infants. METHODS Subnational, population-based studies with high-quality birth outcome data from LMICs were invited to join the Vulnerable Newborn Measurement Collaboration. We defined distinct newborn types using gestational age (preterm [PT], term [T]), birthweight for gestational age using INTERGROWTH-21st standards (small for gestational age [SGA], appropriate for gestational age [AGA] or large for gestational age [LGA]), and birthweight (low birthweight, LBW [<2500 g], nonLBW) as ten types (using all three outcomes), six types (by excluding the birthweight categorisation), and four types (by collapsing the AGA and LGA categories). We defined small types as those with at least one classification of LBW, PT or SGA. We presented study characteristics, participant characteristics, data missingness, and prevalence of newborn types by region and study. RESULTS Among 541 285 live births, 476 939 (88.1%) had non-missing and plausible values for gestational age, birthweight and sex required to construct the newborn types. The median prevalences of ten types across studies were T+AGA+nonLBW (58.0%), T+LGA+nonLBW (3.3%), T+AGA+LBW (0.5%), T+SGA+nonLBW (14.2%), T+SGA+LBW (7.1%), PT+LGA+nonLBW (1.6%), PT+LGA+LBW (0.2%), PT+AGA+nonLBW (3.7%), PT+AGA+LBW (3.6%) and PT+SGA+LBW (1.0%). The median prevalence of small types (six types, 37.6%) varied across studies and within regions and was higher in Southern Asia (52.4%) than in Sub-Saharan Africa (34.9%). CONCLUSIONS Further investigation is needed to describe the mortality risks associated with newborn types and understand the implications of this framework for local targeting of interventions to prevent adverse pregnancy outcomes in LMICs.
Collapse
|
67
|
Mao YS, Gao SG, Li Y, Xue Q, Li F, Jin DH, Yi H, He J. [Hotspots and prospects of esophageal cancer research in China]. ZHONGHUA WEI CHANG WAI KE ZA ZHI = CHINESE JOURNAL OF GASTROINTESTINAL SURGERY 2023; 26:307-311. [PMID: 37072305 DOI: 10.3760/cma.j.cn441530-20221222-00535] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Abstract
Esophageal cancer is a malignant tumor with a high incidence in China. At pesent, advanced esophageal cancer patients are still frequently encountered. The primary treatment for resectable advanced esophageal cancer is surgery-based multimodality therapy, including preoperative neoadjuvant therapy, such as chemotherapy, chemoradiotherapy or chemotherapy plus immunotherapy, followed by radical esophagectomy with thoraco-abdominal two-field or cervico-thoraco-abdominal three-field lymphadenectomy via minimally invasive approach or thoracotomy. In addition, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy, or immunotherapy may also be administered if suggested by postoperative pathological results. Although the treatment outcome of esophageal cancer has improved significantly in China, many clinical issues remain controversial. In this article, we summarize the current hotspots and important issues of esophageal cancer in China, including prevention and early diagnosis, treatment selection for early esophageal cancer, surgical approach selection, lymphadenectomy method, preoperative neoadjuvant therapy, postoperative adjuvant therapy, and nutritional support treatment.
Collapse
|
68
|
Kang XZ, Zhang RX, Wang Z, Chen XK, Qin JJ, Li Y, Xue Q, He J. [Optimization of perioperative treatment strategies for locally advanced esophageal squamous cell carcinoma from the perspective of tumor heterogeneity]. ZHONGHUA WEI CHANG WAI KE ZA ZHI = CHINESE JOURNAL OF GASTROINTESTINAL SURGERY 2023; 26:334-338. [PMID: 37072310 DOI: 10.3760/cma.j.cn441530-20221126-00494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Abstract
Recent advances in multimodality treatment offer excellent opportunities to rethink the paradigm of perioperative management for locally advanced esophageal squamous cell carcinoma. One treatment clearly doesn't fit all in terms of a broad disease spectrum. Individualized treatment of local control of bulky primary tumor burden (advanced T stage) or systemic control of nodal metastatic tumor burden (advanced N stage) is essential. Given that clinically applicable predictive biomarkers are still awaited, therapy selection guided by diverse phenotypes of tumor burden (T vs. N) is promising. Potential challenges regarding the use of immunotherapy may also boost this novel strategy in the future.
Collapse
|
69
|
Zhang XF, Wang Z, Liu WX, Li F, He J, Zhang F, Zhang MY, Qi L, Li Y. [Thoracoscopic laparoscopy-assisted Ivor-Lewis resection of esophagogastric junction cancer]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2023; 45:368-374. [PMID: 37078219 DOI: 10.3760/cma.j.cn112152-20220920-00641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 04/21/2023]
Abstract
Objective: To investigate the outcome of patients with esophagogastric junction cancer undergoing thoracoscopic laparoscopy-assisted Ivor-Lewis resection. Methods: Eighty-four patients who were diagnosed with esophagogastric junction cancer and underwent Ivor-Lewis resection assisted by thoracoscopic laparoscopy at the National Cancer Center from October 2019 to April 2022 were collected. The neoadjuvant treatment mode, surgical safety and clinicopathological characteristics were analyzed. Results: Siewert type Ⅱ (92.8%) and adenocarcinoma (95.2%) were predominant in the cases. A total of 2 774 lymph nodes were dissected in 84 patients. The average number was 33 per case, and the median was 31. Lymph node metastasis was found in 45 patients, and the lymph node metastasis rate was 53.6% (45/84). The total number of lymph node metastasis was 294, and the degree of lymph node metastasis was 10.6%(294/2 774). Among them, abdominal lymph nodes (100%, 45/45) were more likely to metastasize than thoracic lymph nodes (13.3%, 6/45). Sixty-eight patients received neoadjuvant therapy before surgery, and nine patients achieved pathological complete remission (pCR) (13.2%, 9/68). Eighty-three patients had negative surgical margins and underwent R0 resection (98.8%, 83/84). One patient, the intraoperative frozen pathology suggested resection margin was negative, while vascular tumor thrombus was seen on the postoperative pathological margin, R1 resection was performed (1.2%, 1/84). The average operation time of the 84 patients was 234.5 (199.3, 275.0) minutes, and the intraoperative blood loss was 90 (80, 100) ml. One case of intraoperative blood transfusion, one case of postoperative transfer to ICU ward, two cases of postoperative anastomotic leakage, one case of pleural effusion requiring catheter drainage, one case of small intestinal hernia with 12mm poke hole, no postoperative intestinal obstruction, chyle leakage and other complications were observed. The number of deaths within 30 days after surgery was 0. Number of lymph nodes dissection, operation duration, and intraoperative blood loss were not related to whether neoadjuvant therapy was performed (P>0.05). Preoperative neoadjuvant chemotherapy combined with radiotherapy or immunotherapy was not related to whether postoperative pathology achieved pCR (P>0.05). Conclusion: Laparoscopic-assisted Ivor-Lewis surgery for esophagogastric junction cancer has a low incidence of intraoperative and postoperative complications, high safety, wide range of lymph node dissection, and sufficient margin length, which is worthy of clinical promotion.
Collapse
|
70
|
Lu X, Wang R, Li J, Lyu S, Zhang J, Wang Q, Chi W, Zhong R, Chen C, Wu X, Hu R, You Z, Mai Y, Xie S, Lin J, Zheng B, Zhong Q, He J, Liang W. 144P Exposure-lag response of surface net solar radiation on lung cancer incidence: A worldwide interdisciplinary and time-series study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00399-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
71
|
Chen X, He J, Shen H, Xi Y, Chen B, He X, Gao J, Yu H, Shen W. 97P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-risk pathological factors. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00352-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
72
|
Jiang Y, Lin Y, Fu W, Zhong R, He Q, He J, Liang W. 85P The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on patients with stage I non-small cell lung cancer harboring sensitive EGFR mutations. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00340-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
73
|
Lei I, Huang W, Naik S, Maqsood H, He J, Tang P. The Varied Rna Transcript Isoform Landscape During Human Donor Heart Preservation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
74
|
Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, Zeng HM, Wei WW, He J. [Cancer statistics in China, 2016]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2023; 45:212-220. [PMID: 36944542 DOI: 10.3760/cma.j.cn112152-20220922-00647] [Citation(s) in RCA: 19] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2023]
Abstract
Objective: Data for 2016 from cancer registries were used to estimate cancer incidence and mortality in China in 2016. Methods: According to the quality control process of the National Central Cancer Registry, the data from 683 cancer registries submitted by each province were evaluated, and the data of 487 cancer registries were qualified and included in the final analysis. Age-specific incidence and mortality rates were calculated by area (urban/rural), sex, age and cancer site, combined with national population data to estimate cancer incidence and mortality in China in 2016. Chinese population census in 2000 and Segi's population were used for age-standardized incidence and mortality rates. Results: Total population covered by 487 cancer registries was 381 565 422 (192 628 370 in urban and 188 937 052 in rural areas). The percentages of morphologically verified (MV%) and death certificate-only cases (DCO%) accounted for 68.31% and 1.40%, respectively, and the mortality to incidence ratio was 0.61. It was estimated about 4 064 000 new cases occurred in China in 2016, with the crude incidence rate being 293.91/100 000 (the rates of males and females were 315.52/100 000 and 271.23/100 000), age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 190.76/100 000 and 186.46/100 000, with the cumulative incidence rate (0-74 years old) being 21.42%. The crude incidence and ASIRC were 314.74/100 000 and 196.38/100 000 in urban areas, whereas in rural areas, they were 265.90/100 000 and 182.21/100 000, respectively. It was estimated about 2 413 500 cancer deaths occurred in China in 2016, the crude mortality rate was 174.55/100 000 (216.16/100 000 in males and 130.88/100 000 in females), the age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 106.00/100 000 and 105.19/100 000, and the cumulative mortality rate (0-74 years old) was 11.85%. The crude mortality and ASMRC were 180.31/100 000 and 104.44/100 000 in urban areas, whereas in rural areas, they were 166.81/100 000 and 108.01/100 000, respectively. The most common cancer cases include lung, colorectal, stomach, liver and female breast cancers. The top five cancers accounted for about 57.27% of all cancer cases. The most common cancer deaths included lung, liver, stomach, colorectal and esophageal cancers. The top five cancers accounted for about 69.25% of all cancer deaths. Conclusions: The burden of cancer shows a continuous increasing trend in China. Regional and gender differences in cancer burden are obvious. The cancer patterns still show the coexistence of cancer patterns in developed countries and developing countries. The situation of cancer prevention and control is still serious in China.
Collapse
|
75
|
Glenn K, He J, Rochlin R, Teng S, Hecker JG, Novosselov I. Assessment of aerosol persistence in ICUs via low-cost sensor network and zonal models. Sci Rep 2023; 13:3992. [PMID: 36899063 PMCID: PMC10006437 DOI: 10.1038/s41598-023-30778-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Accepted: 03/01/2023] [Indexed: 03/12/2023] Open
Abstract
The COVID-19 pandemic raised public awareness about airborne particulate matter (PM) due to the spread of infectious diseases via the respiratory route. The persistence of potentially infectious aerosols in public spaces and the spread of nosocomial infections in medical settings deserve careful investigation; however, a systematic approach characterizing the fate of aerosols in clinical environments has not been reported. This paper presents a methodology for mapping aerosol propagation using a low-cost PM sensor network in ICU and adjacent environments and the subsequent development of the data-driven zonal model. Mimicking aerosol generation by a patient, we generated trace NaCl aerosols and monitored their propagation in the environment. In positive (closed door) and neutral-pressure (open door) ICUs, up to 6% or 19%, respectively, of all PM escaped through the door gaps; however, the outside sensors did not register an aerosol spike in negative-pressure ICUs. The K-means clustering analysis of temporospatial aerosol concentration data suggests that ICU can be represented by three distinct zones: (1) near the aerosol source, (2) room periphery, and (3) outside the room. The data suggests two-phase plume behavior: dispersion of the original aerosol spike throughout the room, followed by an evacuation phase where "well-mixed" aerosol concentration decayed uniformly. Decay rates were calculated for positive, neutral, and negative pressure operations, with negative-pressure rooms clearing out nearly twice as fast. These decay trends closely followed the air exchange rates. This research demonstrates the methodology for aerosol monitoring in medical settings. This study is limited by a relatively small data set and is specific to single-occupancy ICU rooms. Future work needs to evaluate medical settings with high risks of infectious disease transmission.
Collapse
|
76
|
Segal NA, Nevitt MC, Morales Aquino M, McFadden E, Ho M, Duryea J, Tolstykh I, Cheng H, He J, Lynch JA, Felson DT, Anderson DD. Improved responsiveness to change in joint space width over 24-month follow-up: comparison of 3D JSW on weight-bearing CT vs 2D JSW on radiographs in the MOST study. Osteoarthritis Cartilage 2023; 31:406-413. [PMID: 36526151 PMCID: PMC9974913 DOI: 10.1016/j.joca.2022.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 11/13/2022] [Accepted: 12/06/2022] [Indexed: 12/15/2022]
Abstract
OBJECTIVE Radiographic joint space width (JSW) has been a standard for measuring knee osteoarthritis (OA) structural change. Limitations in the responsiveness of this approach might be overcome by instead measuring 3D JSW on weight-bearing CT (WBCT). This study compared the responsiveness of 3D JSW measurements using WBCT with the responsiveness of radiographic 2D JSW. DESIGN Standing, fixed-flexion knee radiographs (XR) and WBCT were acquired ancillary to the 144- and 168-month Multicenter Osteoarthritis Study visits. Tibiofemoral JSW was measured on both XR and WBCT. Responsiveness to change was defined by the standardized response mean (SRM) for change in JSW (1) at predetermined mediolateral locations (JSWx) on both modalities and (2) in the following subregions measured on WBCT images: central medial and lateral femur (CMF/CLF) and tibia (CMT/CLT), and anterior and posterior tibia (AMT/ALT, PMT/MLT). RESULTS Baseline and 24-month follow-up JSWx measurements were completed for 265 participants (58.1% women). Responsiveness of 3D JSWx for medial tibiofemoral compartment on coronal WBCT (SRM range: -0.18, -0.24) exceeded that for 2D JSWx (-0.10, -0.16). Responsiveness of 3D JSW subregional mean (-0.06, -0.36) and maximal (-1.14, -1.75) CMF and CMT and maximal CLF/CLT 3D JSW changes were statistically significantly greater in comparison with respective medial and lateral 2D JSWx (P ≤ 0.002). CONCLUSIONS Subregional 3D JSW on WBCT is substantially more responsive to 24-month changes in tibiofemoral joint structure compared to radiographic measurements. Use of subregional 3D JSW on WBCT could enable improved detection of OA structural progression over a 24-month duration in comparison with measurements made on XR.
Collapse
|
77
|
ZENG J, Xiao C, Mo Y, Huang J, He J, Yang C, Chen F, Wang Q, Chen S, Wu Y, Wang L, Lu F, Liu L, Liu X, SU G. WCN23-0240 Assessment of physical activity by ActiGraphGT3X accelerometer and its risk factors in chronic kidney disease patients: a cross-sectional study from the PEAKING cohort. Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
78
|
Liu BY, Wang Y, Liu Y, Li J, Cui P, He J. [Research progress of thyroid hormone in pulmonary fibrosis]. ZHONGHUA LAO DONG WEI SHENG ZHI YE BING ZA ZHI = ZHONGHUA LAODONG WEISHENG ZHIYEBING ZAZHI = CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES 2023; 41:62-66. [PMID: 36725299 DOI: 10.3760/cma.j.cn121094-20210727-00377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Pulmonary fibrosis is end-stage of variety of heterogeneous interstitial lung disease, characterizedby excessive proliferation of fibroblasts and extracellular matrix deposition and destruction of lung parenchyma. Thyroid and lung are derived from the same endodermal cells, thyroid hormone affect the occurrence、development and prognosis of the chronic obstructive pulmonary disease, lung cancer and other lung diseases, This article reviews the role and mechanism of thyroid hormone in pulmonary fibrosis in order to provide new idea for the study of the role and mechanism of thyroid hormone in silicosis.
Collapse
|
79
|
Han B, Jiao S, Chen J, Wang Z, Zhao Y, Zhang G, Chen G, Zhou M, Zhou J, Du Y, Wu L, Xu Z, Mei X, Zhang W, He J, Cui J, Zhang Z, Luo H, Liu W, Sun Y. 59MO Final analysis of AK105-302: A randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
80
|
Hu HY, Long L, Dai SA, Yan GQ, Huang Y, He J. Analysis of clinical features, treatment, and prognosis of primary Xlymphoepithelioma-like carcinoma of the lung. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2022; 26:9416-9425. [PMID: 36591850 DOI: 10.26355/eurrev_202212_30693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare lung malignancy occurring most frequently in young non-smokers from Southeast Asia. Given its low incidence, PPLELC clinical features, treatment methods, and the factors affecting its prognosis remain elusive. To date, PPLELC data are mainly derived from clinical case reports, and no cohort studies are available. Therefore, we retrospectively analyzed a group of PPLELC cases and summarized the clinical features of patients, treatment responses, and the factors affecting patient prognosis. PATIENTS AND METHODS A total of 91 patients having primary pulmonary lymphoepithelioma-like carcinoma were recruited in this study. These included sex, age, place of birth, smoking history, pre-treatment symptoms, tumor location, tumor markers, maximum tumor diameter, treatment regimen, lymph node presence metastasis after an operation, pathological picture, immunohistochemistry, genetic findings, and tumor stage grading. We determined the overall survival (OS), progression-free survival (PFS), basic clinical characteristics, treatment option, treatment response, and recurrence pattern among the patients. In addition, we understood the influence of sex, age, tumor, nodes, and metastases (TNM) stage, tumor size, and surgery over patient prognosis. RESULTS Primary pulmonary lymphoepithelioma-like carcinoma is more common among young non-smokers, with a slightly higher incidence in women than in men. The expression of Epstein-Barr virus-encoded small RNA (EBER), pancytokeratin (PCK), Cytokeratin 5/6 (CK5/6), and tumor protein 63 (P63) was positive in immunohistochemistry. Serum cytokeratin 19 fragment antigen (CYFRA21-1) and Epstein-Barr DNA (EB-DNA) could be used as markers to diagnose primary pulmonary lymphoepithelioma-like carcinoma. TNM stage and surgery were independent prognostic factors. CONCLUSIONS Primary pulmonary lymphoepithelioma-like carcinoma is rare, showing a good prognosis.
Collapse
|
81
|
Hwang M, Chia YL, Zheng Y, Chen CCK, He J, Song X, Zhou D, Goldberg SB, Siu LL, Planchard D, Peters S, Mann H, Krug L, Even C. Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance. Br J Clin Pharmacol 2022; 89:1601-1616. [PMID: 36454221 DOI: 10.1111/bcp.15622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Revised: 10/24/2022] [Accepted: 11/22/2022] [Indexed: 12/03/2022] Open
Abstract
AIMS Tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 human monoclonal antibody of the immunoglobulin G2 κ isotype, has been studied in oncology clinical trials as both monotherapy and in combination with durvalumab. This study characterized the pharmacokinetics of tremelimumab as monotherapy and in combination with durvalumab and evaluated the impact of patient covariates on pharmacokinetics. METHODS A pooled-analysis population pharmacokinetics model was built using NONMEM methodology. Pharmacokinetic data from 5 studies spanning different tumour types and therapy regimens were pooled for model development (956 patients). A dataset pooled from 4 additional studies was used for external validation (554 patients). Demographic and relevant clinical covariates were explored during model development. RESULTS Tremelimumab exhibited linear pharmacokinetics, well described by a 2-compartment model, with time-varying clearance (0.276 L/day at baseline) associated primarily with therapy regimen and linked with changes in disease status. As monotherapy and combination therapy, tremelimumab clearance over 1 year increased by ~16% and decreased by ~17%, respectively. Pharmacokinetic behaviour was consistent across patient demographics and cancer subtypes. Patients with higher bodyweight and lower albumin levels at baseline had significantly higher clearance; however, no dosage adjustments are warranted. A flat dose (75 mg) was projected to provide comparable exposure to weight-based dosing (1 mg/kg) in adults. CONCLUSION Tremelimumab exhibited linear pharmacokinetics but consistently opposite trends of time-varying clearance as monotherapy and in combination with durvalumab. Baseline bodyweight and albumin were significant covariates, but conversion from weight-based dosing at 1 mg/kg to flat dosing at 75 mg had no clinically relevant impact.
Collapse
|
82
|
He GL, Pan TY, Liu XX, He SY, Zhang L, Feng WS, Zhang J, He J, Xin W, Zhou YL, Cao XC, He L, Yan YP, You HY, Cui F, Fang XX, Liang QH, Cai M, Chen T, Li L, Wu L. [A multicenter, double-blind, randomized controlled clinical trial comparing ergometrine with oxytocin and oxytocin alone for prevention of postpartum hemorrhage at cesarean section]. ZHONGHUA FU CHAN KE ZA ZHI 2022; 57:836-842. [PMID: 36456480 DOI: 10.3760/cma.j.cn112141-20220630-00427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: To compare oxytocin combined with ergometrine with oxytocin alone in terms of primary prophylaxis for postpartum hemorrhage (PPH) at the time of cesarean section (CS). Methods: This was a multicenter double-blind randomized controlled interventional study comparing ergometrine combined with oxytocin and oxytocin alone administered at CS. From December 2018 to November 2019, a total of 298 parturients were enrolled in 16 hospitals nationwide. They were randomly divided into experimental group (ergometrine intra-myometrial injection following oxytocin intravenously; 148 cases) and control group (oxytocin intra-myometrial injection following oxytocin intravenously; 150 cases) according to 1∶1 random allocation. The following indexes were compared between the two groups: (1) main index: blood loss 2 hours (h) after delivery; (2) secondary indicators: postpartum blood loss at 6 h and 24 h, placental retention time, incidence of PPH, the proportion of additional use of uterine contraction drugs, hemostatic drugs or other hemostatic measures at 2 h and 24 h after delivery, the proportion requiring blood transfusion, and the proportion of prolonged hospital stay due to poor uterine involution; (3) safety indicators: nausea, vomiting, dizziness and other adverse reactions, and blood pressure at each time point of administration. Results: (1) The blood loss at 2 h after delivery in the experimental group [(402±18) ml] was less than that in the control group [(505±18) ml], and the difference was statistically significant (P<0.05). (2) The blood loss at 6 h and 24 h after delivery in the experimental group were less than those in the control group, and the differences were statistically significant (all P<0.05). There were no significant differences between the two groups in the incidence of PPH, the proportion of additional use of uterine contraction drugs, hemostatic drugs or other hemostatic measures at 2 h and 24 h after delivery, the proportion requiring blood transfusion, and the proportion of prolonged hospital stay due to poor uterine involution (all P>0.05). (3) Adverse reactions occurred in 2 cases (1.4%, 2/148) in the experimental group and 1 case (0.7%, 1/150) in the control group. There was no significant difference between the two groups (P>0.05). The systolic blood pressure within 2.0 h and diastolic blood pressure within 1.5 h of drug administration in the experimental group were higher than those in the control group, and the differences were statistically significant (P<0.05), but the blood pressure of the two groups were in the normal range. Conclusion: The use of ergometrine injection in CS could reduce the amount of PPH, which is safe and feasible.
Collapse
|
83
|
Sehgal S, Reddy A, Hill C, Lin T, Zheng L, He J, Herman J, Meyer J, Narang A. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
84
|
Reddy A, Hill C, Sehgal S, He J, Zheng L, Herman J, Meyer J, Narang A. Stereotactic Body Radiation Therapy is Safe and Feasible for the Treatment of Locally Recurrent Pancreatic Adenocarcinoma after Curative Resection. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
85
|
Fan Y, Zhu J, He J, Zhou R, Chen J, Han G, Ren B. 367P High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
86
|
Lin T, Reddy A, Hill C, Sehgal S, He J, Zheng L, Herman J, Meyer J, Narang A. The Optimal Timing of Surgery Following Stereotactic Body Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
87
|
Yang JH, Liu G, Lu S, He J, Burotto M, Vincent S, Yin J, Ma X, Popat S. 319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
88
|
Zhou C, Lu Y, Kim SW, Baisamut (Reungwetwattana) T, Zhou J, Zhang Y, He J, Yang J, Cheng Y, Lee SH, Chang J, Fang J, Liu Z, Bu L, Qian L, Xu T, Archer V, Hilton M, Zhou M, Zhang L. LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
89
|
He J, Guo ZY, Zhou XN. [Improving China's public health emergency response based on One Health theory]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2022; 43:1545-1553. [PMID: 36456485 DOI: 10.3760/cma.j.cn112338-20220606-00502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
With the progress of globalization and the improvement of transportation, a public health emergency can spread across country's boundary in a short period of time from its original place to other areas or regions, posing public health threatens. Public health emergencies not only affect human-animal/plant-environmental health, but also have long-term implications for social development, so the public health emergency response has gone beyond general public health and requires an integrated and comprehensive One Health approach. This paper analyzes the problems and shortcomings of China's current public health emergency response system in a view of One Health and put forward the recommendations based on One Health concept on integrality, collaboration, development and sustainability of public health emergency response. These recommendations can be used as reference to further optimize the response system of public health emergencies in China.
Collapse
|
90
|
Georgiopoulos A, Smith B, Sher Y, Bruce A, He J, Kim J, Chaudhary N, Hardcastle M, Pollinger S, Polineni D, Mohabir P, Shea N, Roach C, Richards C, Miller C, Dvorak M, Quittner A, Friedman D. 312 Barriers to sustaining daily care in adults with cystic fibrosis with mild depression and anxiety. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01002-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
91
|
Jingliang M, Wang K, Murahari P, Yokoyama K, Lord JS, Pratt FL, He J, Schulz L, Willis M, Anthony JE, Morley NA, Nuccio L, Misquitta A, Dunstan DJ, Shimomura K, Watanabe I, Zhang S, Heathcote P, Drew AJ. Reply to: On the observation of photo-excitation effects in molecules using muon spin spectroscopy. NATURE MATERIALS 2022; 21:1110. [PMID: 33972763 DOI: 10.1038/s41563-021-01003-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Accepted: 04/01/2021] [Indexed: 06/12/2023]
|
92
|
Huang H, Sun PY, Zou KY, He J, Zhang YW. [Current situation and prospect of primary prevention of cancer in China]. ZHONGHUA ZHONG LIU ZA ZHI [CHINESE JOURNAL OF ONCOLOGY] 2022; 44:942-949. [PMID: 36164695 DOI: 10.3760/cma.j.cn112152-20220209-00083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Cancer is a major public health issue that seriously endangers the public health and social development of China. Future initiatives for cancer prevention and control should continue to adhere to the principle of prioritizing prevention, and comprehensively implement related prevention activities nationwide. This is critical to reducing cancer burden in Chinese residents, especially in the low- and middle-income populations and those living in areas that are less economically developed. In the past several decades, the international community has significantly reduced the incidence of related cancers through primary prevention measures such as tobacco control, improved occupational hygiene, and vaccination. China has also implemented a series of exploratory primary prevention measures among high-risk groups of cancer in specific areas including Xuanwei, Qidong, and Linxian, and achieved encouraging results. However, due to the low level of systematic awareness of cancer risk factors and the lack of awareness and ability of self-health management in Chinese residents, it is urgent to develop novel research tools and methods to further reveal the causes of cancer, and establish innovative mechanisms and systems of primary prevention of cancer at population and individual levels. Based on current status of the transformation of cancer spectrum and the development of digital intelligence, it would be beneficial to establish a smart digital system for primary cancer prevention service that can cover the entire population, integrating authoritative popular science education on primary prevention of cancer, individualized cancer risk assessment, and personalized health management assistant. This will improve primary cancer prevention among the Chinese general population and can help the sustainable development of cancer prevention and control in China.
Collapse
|
93
|
Li L, He J, Xie YX, Huang XH, Weng XT, Pan XT, Jiao YB, Zheng HH, Qiu LB, Guo WH. [A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2022; 30:939-946. [PMID: 36299187 DOI: 10.3760/cma.j.cn501113-20220823-00432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC)-targeted-immune quadruple therapy in patients with intermediate and advanced-stage hepatocellular carcinoma (HCC). Methods: 101 patients with intermediate and advanced stage HCC were enrolled according to the inclusion and exclusion criteria, and then they were divided into a combination group and a control group. Patients in the combination group was treated with TACE-HAIC-targeted-immune quadruple therapy, while the control group was only treated with TACE therapy. The overall survival (OS), progression-free survival (PFS), and treatment-related adverse reactions were statistically analyzed in the two groups of patients. Statistical analysis was carried out by t-test, χ2 test, rank sum test, Kaplan-Meier curve, log-rank test, Cox regression (or proportional hazards model) analysis according to different data. Results: The tumor objective response rate and disease control rate as evaluated by mRECIST 1.1 criteria in the combination group were 80% and 94%, respectively, which were significantly higher than those in the control group, 41.2% (P<0.001) and 74.5% (P=0.007). The OS and PFS of the combination group were 15.6 months [95%CI 11.3-NA ] and 8.8 months [95%CI 6.9-12.0], respectively, which were significantly better than the control group at 6.1 months [95%CI 5.3-6.6] (P<0.001) and 3.2 months [95%CI 3.0-3.6] (P<0.001). Gastric ulcer incidence was significantly higher in the combination group (9/50, 18%) than that in the control group (2/51, 3.9%) (P=0.023). Conclusion TACE-HAIC-targeted-immune quadruple therapy is a more effective treatment mode for intermediate and advanced-stage HCC than TACE alone, and attention should be paid to the monitoring of target immune-related adverse reactions.
Collapse
|
94
|
Bao J, Guo Z, He J, Leng T, Wei Z, Wang C, Chen F. Semen parameters and sex hormones as affected by SARS-CoV-2 infection: A systematic review. Prog Urol 2022; 32:1431-1439. [PMID: 36153222 PMCID: PMC9468308 DOI: 10.1016/j.purol.2022.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 07/31/2022] [Accepted: 09/05/2022] [Indexed: 11/23/2022]
Abstract
Background Impaired semen quality and reproductive hormone levels were observed in patients during and after recovery from coronavirus disease 2019 (COVID-19), which raised concerns about negative effects on male fertility. Therefore, this study systematically reviews available data on semen parameters and sex hormones in patients with COVID-19. Methods Systematic search was performed on PubMed and Google Scholar until July 18th, 2022. We identified relevant articles that discussed the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on male fertility. Results A total number of 1,684 articles were identified by using a suitable keyword search strategy. After screening, 26 articles were considered eligible for inclusion in this study. These articles included a total of 1,960 controls and 2,106 patients. When all studies were considered, the results showed that the semen parameters and sex hormone levels of patients infected with SARS-CoV-2 exhibited some significant differences compared with controls. Fortunately, these differences gradually disappear as patients recover from COVID-19. Conclusion While present data show the negative effects of SARS-CoV-2 infection on male fertility, this does not appear to be long-term. Semen quality and hormone levels will gradually increase to normal as patients recover.
Collapse
|
95
|
Xiao JY, He J, Huang SM, Chen ZM. [Progress in application of metabolomics in childhood bronchial asthma]. ZHONGHUA ER KE ZA ZHI = CHINESE JOURNAL OF PEDIATRICS 2022; 60:960-963. [PMID: 36038313 DOI: 10.3760/cma.j.cn112140-20220613-00546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
96
|
He J, Wang B, Tao J, Liu Q, Peng M, Qiu X, Yang Y, Ye Z, Liu D, W. li, Chen Z, Zeng Q, Fan J, Liang W. 905MO Synergistic combination of clinical, imaging and DNA methylation biomarkers improves the classification of pulmonary nodules. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
97
|
Hecker JG, He J, Rochlin R, Brannen C, Teng S, Glenn K, Novosselov I. Measuring aerosols in the operating theatre and beyond using a real-time sensor network. Anaesthesia 2022; 77:1097-1105. [PMID: 36047649 DOI: 10.1111/anae.15842] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2022] [Indexed: 11/27/2022]
Abstract
The ability to measure and track aerosols in the vicinity of patients with suspected or confirmed COVID-19 is highly desirable. At present, there is no way to measure and track, in real time, the sizes, dispersion and dilution/disappearance of aerosols that are generated by airway manipulations such as mask ventilation; tracheal intubation; bronchoscopy; dental and gastro-intestinal endoscopy procedures; or by vigorous breathing, coughing or exercise. We deployed low-cost photoelectric sensors in five operating theatres between surgical cases. We measured and analysed dilution and exfiltration of aerosols we generated to evaluate air handling and dispersion under real-world conditions. These data were used to develop a model of aerosol persistence. We found significant variation between different operating theatres. Equipment placement near air vents affects air flows, impacting aerosol movement and elimination patterns. Despite these impediments, air exchange in operating theatres is robust and prolonged fallow time before theatre turnover may not be necessary. Significant concentrations of aerosols are not seen in adjoining areas outside of the operating theatre. These models and dispersion rates can predict aerosol persistence in operating theatres and other clinical areas and potentially facilitate quantification of risk, with obvious and far-reaching implications for designing, evaluating and confirming air handling in non-medical environments.
Collapse
|
98
|
Che Y, Luo Z, Cao Y, Sun N, Xue Q, He J. 1178P Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
99
|
Parikh A, Murugesan K, Hopkins J, Arshad Z, Jin D, Klempner S, Fabrizio D, Frampton G, He J, Montesion M. 97P Pan-cancer landscape of clonal tumor mutational burden (cTMB). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
100
|
Singhi A, Chen T, Madison R, Bhardwaj N, Jin D, Fleischmann Z, Newberg J, Moore J, Frampton G, Hegde P, Fabrizio D, He J, Schrock A, Ebot E, Sokol E. 1300P Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|